Meerim Park1, Jun Ah Lee1, Hye Young Jin1, Joo-Young Kim2, Jong Woong Park3, June Hyuk Kim3, Hyun Guy Kang3, Seog Yun Park4, Eun Young Park5, Hyeon Jin Park1, Byung Kiu Park6,7. 1. Department of Pediatrics, Center for Pediatric Cancer, National Cancer Center, Goyang, Korea. 2. Radiation Oncology, Center for Pediatric Cancer, National Cancer Center, Goyang, Korea. 3. Orthopaedic Oncology Clinic, Center for Rare Cancer, National Cancer Center, Goyang, Korea. 4. Department of Pathology, National Cancer Center, Goyang, Korea. 5. Biostatistics Collaboration Team, Research Core Center, National Cancer Center, Goyang, Korea. 6. Department of Pediatrics, Center for Pediatric Cancer, National Cancer Center, Goyang, Korea. bykipark@naver.com. 7. Department of Pediatrics, Seoul Metropolitan Seonam Hospital, Seoul, Korea. bykipark@naver.com.
Abstract
PURPOSE: This study aimed to analyze characteristics, treatment, long-term outcomes, and prognostic factors for children, adolescents and young adults with rhabdomysosarcoma (RMS). METHODS: This retrospective historical study included 75 patients with RMS treated between 2002 and 2019. Clinical data and follow-up results were collected including all diagnosis, treatment and prognosis information. RESULTS: Patients median-age-at-diagnosis was 6 years. Embryonal and alveolar histology occurred in 51 (68.0%) and 21 (28.0%) patients, respectively. The tumors most frequently originated from parameningeal site (28.0%). Of 74 evaluable patients for treatment outcome, 60 (81.1%) achieved complete response for first-line treatment, of whom, 34 (56.6%) maintained complete response, 26 (43.3%; 23/26, local relapse) showed relapse. Of 40 patients with treatment failure, 16 and 6 occurred in parameningeal area and retroperitoneum/perineum, respectively. The 5-year progression-free survival (PFS) and overall survival (OS) were 45.0% and 64.5%, respectively. In multivariate analyses, parameningeal site (p = 0.027), no gross total resection (p = 0.047), and no radiation therapy (RT) (p < 0.001) for PFS; and parameningeal site (p < 0.001) and no RT (p = 0.010) for worse OS, were significant. The median PFS and OS from treatment failure date in 40 patients with primary treatment failure were 1.3 and 4.1 years, respectively. Of 26 patients with relapse, interval to relapse < 7 months, retroperitoneum/perineum site, TNM stages III/IIV, and no salvage RT were independently associated with OS. CONCLUSION: The importance of adequate local therapy was highlighted in RMS treatment. Treatment failure was largely a local failure. Whether as a component of initial or salvage treatment, RT could improve patients' survival.
PURPOSE: This study aimed to analyze characteristics, treatment, long-term outcomes, and prognostic factors for children, adolescents and young adults with rhabdomysosarcoma (RMS). METHODS: This retrospective historical study included 75 patients with RMS treated between 2002 and 2019. Clinical data and follow-up results were collected including all diagnosis, treatment and prognosis information. RESULTS: Patients median-age-at-diagnosis was 6 years. Embryonal and alveolar histology occurred in 51 (68.0%) and 21 (28.0%) patients, respectively. The tumors most frequently originated from parameningeal site (28.0%). Of 74 evaluable patients for treatment outcome, 60 (81.1%) achieved complete response for first-line treatment, of whom, 34 (56.6%) maintained complete response, 26 (43.3%; 23/26, local relapse) showed relapse. Of 40 patients with treatment failure, 16 and 6 occurred in parameningeal area and retroperitoneum/perineum, respectively. The 5-year progression-free survival (PFS) and overall survival (OS) were 45.0% and 64.5%, respectively. In multivariate analyses, parameningeal site (p = 0.027), no gross total resection (p = 0.047), and no radiation therapy (RT) (p < 0.001) for PFS; and parameningeal site (p < 0.001) and no RT (p = 0.010) for worse OS, were significant. The median PFS and OS from treatment failure date in 40 patients with primary treatment failure were 1.3 and 4.1 years, respectively. Of 26 patients with relapse, interval to relapse < 7 months, retroperitoneum/perineum site, TNM stages III/IIV, and no salvage RT were independently associated with OS. CONCLUSION: The importance of adequate local therapy was highlighted in RMS treatment. Treatment failure was largely a local failure. Whether as a component of initial or salvage treatment, RT could improve patients' survival.
Authors: Gianni Bisogno; Gian Luca De Salvo; Christophe Bergeron; Soledad Gallego Melcón; Johannes H Merks; Anna Kelsey; Helene Martelli; Veronique Minard-Colin; Daniel Orbach; Heidi Glosli; Julia Chisholm; Michela Casanova; Ilaria Zanetti; Christine Devalck; Myriam Ben-Arush; Peter Mudry; Sima Ferman; Meriel Jenney; Andrea Ferrari Journal: Lancet Oncol Date: 2019-09-24 Impact factor: 41.316
Authors: W M Crist; J R Anderson; J L Meza; C Fryer; R B Raney; F B Ruymann; J Breneman; S J Qualman; E Wiener; M Wharam; T Lobe; B Webber; H M Maurer; S S Donaldson Journal: J Clin Oncol Date: 2001-06-15 Impact factor: 44.544
Authors: Scott C Borinstein; Diana Steppan; Masanori Hayashi; David M Loeb; Michael S Isakoff; Odion Binitie; Andrew S Brohl; Julia A Bridge; Mark Stavas; Eric T Shinohara; William H Meyer; Damon R Reed; Lars M Wagner Journal: Pediatr Blood Cancer Date: 2017-09-14 Impact factor: 3.167
Authors: Lucas L de Souza; Hélder A R Pontes; Alan R Santos-Silva; Lais A Fernandes; Luana A L Batista; Márcio A Lopes; Waqas Khan; Flávia S C Pontes Journal: Head Neck Date: 2020-04-28 Impact factor: 3.147
Authors: Tobias M Dantonello; Christoph Int-Veen; Andreas Schuck; Guido Seitz; Ivo Leuschner; Michaela Nathrath; Paul-Gerhardt Schlegel; Udo Kontny; Wolfgang Behnisch; Iris Veit-Friedrich; Stefanie Kube; Erika Hallmen; Bernarda Kazanowska; Ruth Ladenstein; Michael Paulussen; Gustaf Ljungman; Stefan S Bielack; T Klingebiel; E Koscielniak Journal: Pediatr Blood Cancer Date: 2013-02-15 Impact factor: 3.167
Authors: S C Clement; R A Schoot; O Slater; J C Chisholm; C Abela; A J M Balm; M W van den Brekel; W B Breunis; Y C Chang; R Davila Fajardo; D Dunaway; E Gajdosova; M N Gaze; S Gupta; B Hartley; L C M Kremer; M van Lennep; G A Levitt; H C Mandeville; B R Pieters; P Saeed; L E Smeele; S D Strackee; C M Ronckers; H N Caron; H M van Santen; J H M Merks Journal: Eur J Cancer Date: 2015-12-17 Impact factor: 9.162
Authors: Alison L Cameron; Markus C Elze; Michela Casanova; Birgit Geoerger; Mark N Gaze; Veronique Minard-Colin; Kieran McHugh; Rick R van Rijn; Anna Kelsey; Hélène Martelli; Henry Mandeville; Gianni Bisogno; Stephen Lowis; Milind Ronghe; Daniel Orbach; Cecile Guizani; Sabine Fürst-Recktenwald; Julia C Chisholm; Johannes H M Merks Journal: Int J Radiat Oncol Biol Phys Date: 2021-07-01 Impact factor: 7.038